Abstract: The Faecal Immunochemical Test (FIT) detected advanced neoplasms (ANs) with the highest accuracy in the 40–49 age group. This research provides critical guidance for formulating colorectal cancer (CRC) screening strategies, particularly regarding the optimal starting age for screening.
Introduction
Colorectal cancer (CRC) remains a leading cause of global mortality, yet it is highly preventable through early detection. While traditional screening programs target adults over 50, there is a rising incidence of "early-onset" CRC in younger populations. The Faecal Immunochemical Test (FIT) is widely used as a non-invasive, cost-effective screening tool. However, its diagnostic performance—including sensitivity, specificity, and overall accuracy—can vary significantly based on demographic factors. This study quantifies these differences across age and sex to help refine screening strategies for younger, at-risk populations.
Methods
Researchers conducted a cross-sectional study of 39,991 individuals participating in the Tianjin CRC screening program between 2012 and 2020. Every participant received both a quantitative FIT (cut-off value of 100 ng/mL) and a follow-up colonoscopy. The colonoscopy results served as the "gold standard" to measure FIT performance. The study population was divided into four age cohorts: 40–49, 50–59, 60–69, and ≥70. Performance was evaluated using Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value (NPV), and overall Accuracy.
Key Results and Insights
Peak Accuracy in Younger Cohorts
Counter-intuitively, the FIT achieved its highest diagnostic accuracy in the youngest group (40–49 years). While diagnostic tests often perform better in high-prevalence populations, the FIT outperformed its results in older groups despite the lower prevalence of disease in younger adults.
As shown in the data, accuracy was 54.9% in the 40–49 group, compared to 45.4% in the 50–59 group and 49.5% in those aged 70 and older.
Sex-Based Disparities and Predictive Power
The study revealed a striking sex-based disparity: males were generally more likely to develop advanced neoplasms (ANs) than females across all age groups. Furthermore, the FIT's predictive power varied by sex. In the 40–49 age group, the Negative Predictive Value (NPV) was remarkably high—76.8% for females—suggesting the FIT is an exceptionally strong tool for "ruling out" advanced disease in younger women.
Symptom-Accuracy Correlation
Beyond demographics, clinical symptoms were found to correlate with test performance. A history of chronic diarrhea, chronic constipation, or having a first-degree relative with CRC not only indicated a higher risk of cancer but also significantly improved the diagnostic accuracy of the FIT.
Conclusion and Future Directions
These findings support the global trend toward lowering the recommended age for initial CRC screening. The high accuracy of the FIT in the 40–49 age bracket suggests that starting screening at age 40 or 45 could significantly improve early detection and outcomes.
While the study is limited by potential selection bias (as participants were already identified as "high risk") and a smaller sample size in the youngest cohort, the statistical significance of the results is robust. Future research should focus on why FIT sensitivity appears lower in high-risk cohorts compared to general-population studies and continue to refine sex-specific risk assessment models.
Summary updated